India’s Biocon Biologics says the European Medicines Agency’s recent endorsement of the Inpremzia biosimilar fast-acting human insulin rival to Actrapid represents a “milestone” for the company as it continues its efforts to expand access to insulin products.
In late February, the EMA’s committee for medicinal products for human use issued a positive opinion recommending that Inpremzia – a ready-to-use insulin formulation for intravenous infusion developed by Celerity Pharmaceuticals, using Biocon Biologics’ biosimilar human insulin drug substance – be granted a pan-European marketing authorization, with the application filed through Baxter Holding B.V
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?